These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1776885)

  • 21. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
    Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
    Kontoghiorghes GJ
    Scand J Haematol; 1986 Jul; 37(1):63-70. PubMed ID: 3764334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New therapeutic trends in thalassemia: oral chelating agents].
    Carnelli V; Terzoli S; Fossati G; Careddu G; Perri M; Pedrotti L; Mirra N
    Pediatr Med Chir; 1992; 14(3):273-5. PubMed ID: 1528794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
    al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
    J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
    Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
    J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
    Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral iron chelators.
    Cappellini MD; Pattoneri P
    Annu Rev Med; 2009; 60():25-38. PubMed ID: 19630568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron chelation therapy.
    Hershko CM; Link GM; Konijn AM; Cabantchik ZI
    Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro.
    Cunningham JM; al-Refaie FN; Hunter AE; Sheppard LN; Hoffbrand AV
    Eur J Haematol; 1994 Mar; 52(3):176-9. PubMed ID: 8168597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferiprone as an oral iron chelator in sickle cell disease.
    Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
    Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring.
    Waterhouse DM; Calzone KA; Mele C; Brenner DE
    J Clin Oncol; 1993 Jun; 11(6):1189-97. PubMed ID: 8501505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.